ReShape Lifesciences has secured a $241,000 supplementary grant from the NIH to advance the development of its Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system, a device aimed at managing Type 2 diabetes. The grant will support further preclinical trials using the DBSN™ device, including the development of next-generation electrodes to improve treatment efficacy and reduce power consumption.

ReShape Lifesciences’ DBSN™ system combines vagus nerve block and stimulation to regulate blood glucose levels. The enhancement initiative reflects the company’s ongoing commitment to improving personalized diabetes care through bioelectronic technology. The system is designed to reduce the need for medication by leveraging electrical neuromodulation to regulate insulin production and glucose release, potentially addressing challenges like medication non-compliance and treatment costs.

For consumers, particularly those affected by Type 2 diabetes, this technology offers hope for a minimally invasive treatment alternative with the potential to reduce reliance on drugs and improve glycemic control.